Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease
Talha Munir(Leeds Teaching Hospitals NHS Trust), Peter Hillmen(Leeds Teaching Hospitals NHS Trust), Oonagh Sheehy(University of Leeds), Andrew R. Pettitt(University of Liverpool), Ben Kennedy(University of Leeds), Natasha Greatorex(University of Leeds), Sue Bell(University of Leeds), Kate Cwynarski(University of Leeds), Julia Brown(University of Leeds), Adrian Bloor(The Christie NHS Foundation Trust), David Allsup(University of Leeds), David A. Cairns(BMW (Germany)), Nagah Elmusharaf(University of Leeds), Piers Patten, Toby A. Eyre(Churchill Hospital), Shankara Paneesha(University of Leeds), John G. Gribben(Queen Mary University of London), Lelia Duley(Bradford Royal Infirmary), Sharon Jackson(University of Leeds), Dena Howard(University of Leeds), Anna Hockaday(University of Leeds), Anna Schuh(National Institute for Health Research), Francesco Forconi(University of Leeds), Nichola Webster(University of Leeds), Christopher P. Fox(Nottingham University Hospitals NHS Trust), Ruth de Tute(Leeds Teaching Hospitals NHS Trust), Nicholas Pemberton(University of Leeds), Surita Dalal(University of Leeds), Sean Girvan(University of Leeds), Andy C. Rawstron(St James's University Hospital), Gavin Preston(University of Leeds), Renata Walewska(Dorset HealthCare University NHS Foundation Trust)
Cited by 155
Related Papers
High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma
|New England Journal of Medicine|2003|1.8k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k